Amgen and Allergan announced today that the companies have submitted a Biologics License Application for ABP 980, a proposed trastuzumab (Herceptin) biosimilar.
Amgen and Allergan announced today that the companies have submitted a Biologics License Application (BLA) for ABP 980, a proposed trastuzumab (Herceptin) biosimilar.
The companies’ BLA submission includes data from a phase 3 comparative efficacy, safety, and immunogenicity study conducted in adult female patients with HER2-positive early breast cancer. The partnership also filed for approval of the product with the European Union’s European Medicines Agency in March of 2017.
"The submission of ABP 980 for FDA review is an exciting milestone and speaks to our joint commitment with Allergan to deliver quality oncology biosimilars to patients," said Sean E. Harper, MD, executive vice president of research and development at Amgen. "Approval of ABP 980 would provide more patients access to a high-quality therapy with a proven safety and efficacy profile. We look forward to further discussions with the FDA."
Allergan’s chief of research and development, David Nicholson, added, "We're proud of the progress we've made so far and look forward to continuing our work to bring more biosimilars to market."
US-based Amgen and Ireland-based Allergan are collaborating on 4 biosimilar products, including ABP 980, for oncology indications. In July, the partnership received a unanimous recommendation for approval from the FDA’s Oncologic Drugs Advisory Committee (ODAC) for another of those products, ABP 215, a proposed bevacizumab (Avastin) biosimilar. The FDA’s decision on ABP 215 is expected in September.
The Amgen—Allergan partnership’s filing comes just 1 day after Celltrion and Teva announced a trastuzumab biosimilar BLA of their own. The Celltrion—Teva product, CT-P6, also relies on data from a phase 3 equivalence trial in patients with HER2-postive early breast cancer.
However, the first biosimilar trastuzumab product expected to penetrate the US market is Mylan and Biocon’s trastuzumab, MYL-1401O, which has a Biosimilar User Fee Act date of September 3, 2017. The product recently received a unanimous ODAC recommendation for approval. The Mylan—Biocon product is expected to be the first biosimilar challenger to the reference Herceptin after Mylan entered a global settlement with the reference product’s sponsor, Genetech, in March. The settlement has provided Mylan with a global license to commercialize MYL-1401O after approval.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.